Pfizer: No evidence COVID-19 variants result in a loss of protection provided by vaccine
|Pfizer announced on Thursday that they haven't seen any evidence that circulating variants of the coronavirus result in a loss of protection provided by the vaccine they developed with BioNTech, as reported by Reuters.
"We haven't observed changes to neutralizing antibody levels that would predict a significant reduction in protection given by 2 doses of BNT162B2," Pfizer further noted.
Market reaction
This headline doesn't seem to be having a significant impact on market sentiment. As of writing, the S&P 500 Futures were down 0.3% on a daily basis at 3,910.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.